Amgen Inc. has raised its revenue and profit forecasts for the third time this year after reporting stronger-than-expected sales for several key medicines. The company now projects annual revenue between $38.9 billion and $39.7 billion, up from its previous guidance of $38.2 billion to $39.4 billion issued in August. Adjusted profits are expected to range between $22.90 and $23.70 per share.
The latest revision reflects continued momentum in Amgen's core products, which have outperformed market expectations. This upward adjustment comes as the biotech giant continues to benefit from robust demand for its therapeutic portfolio. The company's optimistic outlook signals confidence in its ability to sustain growth despite competitive pressures in the pharmaceutical industry.
Amgen's decision to raise its forecast underscores its strong financial performance this year. The company has consistently exceeded analyst estimates, reinforcing its position as a leader in the biotechnology sector. Investors and industry watchers will be closely monitoring how these projections translate into actual results in the coming quarters.